Does anyone know if NASDAQ considers executive compensation, and the number of shares granted to company executives, in deciding whether to grant a listing?
If so, the past and impending share grants to Pourhassan would not bode well for Cytodyn being able to uplist to NASDAQ, in my opinion.
LM
(1)
(0)
CytoDyn Inc (CYDY) Stock Research Links
The Lawmanstyle="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]